Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000469078 | SCV000542169 | likely benign | Neurofibromatosis, type 1 | 2024-10-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000681013 | SCV000808462 | uncertain significance | not provided | 2022-04-19 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV002318995 | SCV001172040 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-04-27 | criteria provided, single submitter | clinical testing | The p.Y49N variant (also known as c.145T>A), located in coding exon 2 of the NF1 gene, results from a T to A substitution at nucleotide position 145. The tyrosine at codon 49 is replaced by asparagine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000469078 | SCV002561411 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing |